The money will help the Franklin Lakes, N.J.-based company boost its production capacity by 50 percent and produce more than 12 million test kits per month by next February, it said.
“Making COVID-19 diagnostic tests widely available is critical to expanding rapid detection of COVID-19 infections and mitigating the impact of the disease by identifying affected patients, quickly quarantining infectious individuals and tracing their contacts,” said Dave Hickey, Beckton, Dickinson & Co.’s president of integrated diagnostic solutions. “This investment will bolster our U.S. manufacturing capabilities, helping us quickly scale our production of point-of-care COVID-19 tests to ensure we have a robust supply for our U.S. customers.”
Read the full news release here.
More articles on supply chain:
FDA puts hand sanitizers on import alert, adds more to do-not-use list
Freight, shipping companies say they’re not ready to distribute COVID-19 vaccine
See-through masks in high demand as COVID-19 cases rise
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
